Literature DB >> 2733126

Markers of HIV infection prior to IgG antibody seropositivity.

S L Stramer1, J S Heller, R W Coombs, J V Parry, D D Ho, J P Allain.   

Abstract

During a 1-year period of study at two plasma collection centers, 7 of 35,000 plasma donors seroconverted to the human immunodeficiency virus (HIV) and had stored plasma samples that predated or antedated the seroconversion period. From each donor, three to eight plasma samples that had been collected at 2- to 7-day intervals were tested for IgG and IgM antibodies to HIV with enzyme immunoassays, Western blot testing, and radioimmunoprecipitation assays. The presence of an HIV viremic phase was demonstrated by the infectivity of plasma on normal, phytohemagglutinin-stimulated peripheral blood mononuclear cells and by the detection of HIV antigen. In 5 of these donors, HIV antigen was detected prior to or simultaneously with IgG to HIV; these HIV-antigen-positive samples overlapped an IgM immune response. The disappearance of detectable HIV antigen, and to a lesser extent plasma infectivity, was concurrent with the development of an IgG immune response. Although the improved sensitivity of a recombinant DNA-derived anti-HIV screening assay shortened the "window period" between initial HIV infection and antibody detection, HIV antigen and plasma HIV viremia were the only markers of HIV infection for several days in 2 donors. These results demonstrate that HIV plasma viremia and antigenemia occur prior to seroconversion in healthy plasma donors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2733126

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  14 in total

1.  Performance of a multiplex qualitative PCR LCx assay for detection of human immunodeficiency virus type 1 (HIV-1) group M subtypes, group O, and HIV-2.

Authors:  K Abravaya; C Esping; R Hoenle; J Gorzowski; R Perry; P Kroeger; J Robinson; R Flanders
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  New sensitive and specific assay for human immunodeficiency virus antibodies using labeled recombinant fusion protein and time-resolved fluoroimmunoassay.

Authors:  H Siitari; P Turunen; J Schrimsher; M Nunn
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

Review 3.  Clinical, virological and immunological features of primary HIV-1 infection.

Authors:  M D de Jong; H J Hulsebosch; J M Lange
Journal:  Genitourin Med       Date:  1991-10

4.  Multicenter evaluation of new double-antigen sandwich enzyme immunoassay for measurement of anti-human immunodeficiency virus type 1 and type 2 antibodies.

Authors:  P Burgisser; F Simon; M Wernli; T Wust; M F Beya; P C Frei
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

5.  A field test for the detection of antibodies to human immunodeficiency virus types 1 and 2 in serum or plasma.

Authors:  A Burgess-Cassler; G Barriga Angulo; S E Wade; P Castillo Torres; W Schramm
Journal:  Clin Diagn Lab Immunol       Date:  1996-07

6.  Humoral immune response to the bovine immunodeficiency-like virus in experimentally and naturally infected cattle.

Authors:  C A Whetstone; M J VanDerMaaten; J W Black
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

Review 7.  More reliable diagnosis of infection with human immunodeficiency virus type 1 (HIV-1) by detection of antibody IgGs to pol and gag proteins of HIV-1 and p24 antigen of HIV-1 in urine, saliva, and/or serum with highly sensitive and specific enzyme immunoassay (immune complex transfer enzyme immunoassay): a review.

Authors:  S Hashida; K Hashinaka; S Ishikawa; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

8.  Early detection of antibody to human immunodeficiency virus type 1 by using an antigen conjugate immunoassay correlates with the presence of immunoglobulin M antibody.

Authors:  J L Gallarda; D R Henrard; D Liu; S Harrington; S L Stramer; J E Valinsky; P Wu
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

9.  Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  D C Montefiori; B S Graham; S Kliks; P F Wright
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

10.  Immune complex transfer enzyme immunoassay that is more sensitive and specific than western blotting for detection of antibody immunoglobulin G to human immunodeficiency virus type 1 in serum with recombinant pol and gag proteins as antigens.

Authors:  S Hashida; K Hashinaka; I Nishikata; S Oka; K Shimada; A Saito; A Takamizawa; H Shinagawa; S Yano; H Kojima
Journal:  Clin Diagn Lab Immunol       Date:  1995-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.